In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Nancy Dvorin

Managing Editor

Connecticut, US
Nancy Dvorin joined the IN VIVO staff in 1999 to report on emerging life science companies. She has been managing editor of the publication since 2009, and responsible for producing IN VIVO’s insightful coverage of the biopharma, medtech and diagnostics industries. Before joining IN VIVO, Nancy managed library and information services for a number of multinational corporations. She’s delighted that her passion for delivering useful, actionable intelligence to clients has translated well from the information service to the information provider arena.
Advertisement
Set Alert for Articles By Nancy Dvorin

Latest From Nancy Dvorin

Guidelines For Contributing Authors

Free: In Vivo welcomes contributions from thought leaders in the life sciences industry. We've posted some guidelines to help you get started.

BioPharmaceutical Medical Device

In Vivo's Deals Of The Month, March 2017

Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.

Deals Market Intelligence

Personalized Medicine: An Infographic

Free content: There were 132 personalized medicines on the market in 2016, compared with just five in in 2008, according to the Personalized Medicine Coalition. And 27% of new molecular entities approved by the FDA in 2016 can be can be classified as a personalized medicine. That's a big jump from 2005, when personalized medicines accounted for just 5% of NME approvals. A look at some other key numbers in this rapidly growing field.

BioPharmaceutical Market Intelligence

Personalized Medicine: A Trip Down Memory Lane

Free article: What In Vivo has been saying about personalized medicine in this century.

BioPharmaceutical Personalized Medicine

In Vivo's Deals Of The Month, February 2017

Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.

BioPharmaceutical Medical Device

In Vivo's Deals Of The Month, January 2017

In Vivo's editors pick January's most significant deals, including J&J's Actelion acquisition and a big launch for Vir Biotechnology. (Article free with registration.)

Deals Market Intelligence
See All
Advertisement
UsernamePublicRestriction

Register